These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 16937443)
1. Correlation of p53 gene mutation and expression of P53 protein in cholangiocarcinoma. Liu XF; Zhang H; Zhu SG; Zhou XT; Su HL; Xu Z; Li SJ World J Gastroenterol; 2006 Aug; 12(29):4706-9. PubMed ID: 16937443 [TBL] [Abstract][Full Text] [Related]
2. p53 Mutations in human cholangiocarcinoma: a review. Khan SA; Thomas HC; Toledano MB; Cox IJ; Taylor-Robinson SD Liver Int; 2005 Aug; 25(4):704-16. PubMed ID: 15998419 [TBL] [Abstract][Full Text] [Related]
3. Correlation between promoter methylation of p14(ARF), TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma. Xiaofang L; Kun T; Shaoping Y; Zaiqiu W; Hailong S World J Surg Oncol; 2012 Jan; 10():5. PubMed ID: 22230750 [TBL] [Abstract][Full Text] [Related]
4. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas. Della Torre G; Pasquini G; Pilotti S; Alasio L; Civelli E; Cozzi G; Milella M; Salvetti M; Pierotti MA; Severini A Diagn Mol Pathol; 2000 Mar; 9(1):41-6. PubMed ID: 10718212 [TBL] [Abstract][Full Text] [Related]
5. New p53 mutations in hilar cholangiocarcinoma. Tullo A; D'Erchia AM; Honda K; Kelly MD; Habib NA; Saccone C; Sbisà E Eur J Clin Invest; 2000 Sep; 30(9):798-803. PubMed ID: 10998080 [TBL] [Abstract][Full Text] [Related]
6. Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma. Khan SA; Taylor-Robinson SD; Carmichael PL; Habib N; Lemoine NR; Thomas HC Int J Oncol; 2006 May; 28(5):1269-77. PubMed ID: 16596244 [TBL] [Abstract][Full Text] [Related]
7. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215 [TBL] [Abstract][Full Text] [Related]
8. [Result of p53, ki-67 protein expression in cholangiocarcinoma with in situ hybridization and immunohistochemistry methods]. Wang X; Zhang J; Chen J Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):57-60. PubMed ID: 12903495 [TBL] [Abstract][Full Text] [Related]
9. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. Tannapfel A; Sommerer F; Benicke M; Weinans L; Katalinic A; Geissler F; Uhlmann D; Hauss J; Wittekind C J Pathol; 2002 Aug; 197(5):624-31. PubMed ID: 12210082 [TBL] [Abstract][Full Text] [Related]
10. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Tannapfel A; Engeland K; Weinans L; Katalinic A; Hauss J; Mössner J; Wittekind C Br J Cancer; 1999 Jun; 80(7):1069-74. PubMed ID: 10362118 [TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. Momoi H; Itoh T; Nozaki Y; Arima Y; Okabe H; Satoh S; Toda Y; Sakai E; Nakagawara K; Flemming P; Yamamoto M; Shimahara Y; Yamaoka Y; Fukumoto M J Hepatol; 2001 Aug; 35(2):235-44. PubMed ID: 11580146 [TBL] [Abstract][Full Text] [Related]
12. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Kiba T; Tsuda H; Pairojkul C; Inoue S; Sugimura T; Hirohashi S Mol Carcinog; 1993; 8(4):312-8. PubMed ID: 8280380 [TBL] [Abstract][Full Text] [Related]
13. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Tannapfel A; Weinans L; Geissler F; Schütz A; Katalinic A; Köckerling F; Hauss J; Wittekind C Dig Dis Sci; 2000 Feb; 45(2):317-24. PubMed ID: 10711445 [TBL] [Abstract][Full Text] [Related]
14. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Sugimachi K; Taguchi K; Aishima S; Tanaka S; Shimada M; Kajiyama K; Sugimachi K; Tsuneyoshi M Mod Pathol; 2001 Sep; 14(9):900-5. PubMed ID: 11557787 [TBL] [Abstract][Full Text] [Related]
15. K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients. Petmitr S; Pinlaor S; Thousungnoen A; Karalak A; Migasena P Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):71-5. PubMed ID: 9740272 [TBL] [Abstract][Full Text] [Related]
18. Effect of Mir-122 on Human Cholangiocarcinoma Proliferation, Invasion, and Apoptosis Through P53 Expression. Wu C; Zhang J; Cao X; Yang Q; Xia D Med Sci Monit; 2016 Jul; 22():2685-90. PubMed ID: 27472451 [TBL] [Abstract][Full Text] [Related]
19. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. Boberg KM; Schrumpf E; Bergquist A; Broomé U; Pares A; Remotti H; Schjölberg A; Spurkland A; Clausen OP J Hepatol; 2000 Mar; 32(3):374-80. PubMed ID: 10735605 [TBL] [Abstract][Full Text] [Related]
20. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Isa T; Tomita S; Nakachi A; Miyazato H; Shimoji H; Kusano T; Muto Y; Furukawa M Hepatogastroenterology; 2002; 49(45):604-8. PubMed ID: 12063950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]